Submitted by The Cannabis Business Advisors
With the U.S. cannabis market expected to reach more than $30 billion by 2025, license opportunities abound for investors and current license holders. There are six states in the midwest and south with new medical cannabis licenses available, four states with both medical and adult-use license processes on the calendar, and nine states with adult-use marijuana opportunities spanning from Arizona to Maine, and as far south as Virginia. Many stakeholders are turning their attention to mid-Atlantic powerhouses New York and New Jersey, two states that legalized adult-use marijuana within five months of one another and have the potential to make a big industry impact.
National consulting firm The Cannabis Business Advisors (“CB Advisors”), led by CEO and Founder Sara Gullickson, is focused on these emerging east coast markets. New York is expected to reach $4.2B in annual sales by 2027 and according to the Marijuana Policy Project, the entire Northeast region, including New Jersey, Connecticut, Massachusetts and Vermont, is expected to generate $8.7 billion in sales by that year.
Gullickson, who has been actively involved in the industry for over a decade, has helped develop regulatory frameworks for new marijuana programs on an international and national scale and has secured license permits for multiple groups in 18 state markets.
Through her custom consulting work at CB Advisors, Gullickson and her team guide applicant teams on how to identify opportunities best suited for their strengths and expertise. Despite the close proximity between New York and New Jersey, there are key differences in how the states are pursuing adult-use marijuana policy and …